No registrations found.
ID
Source
Brief title
Health condition
COVID-19
Sponsors and support
Intervention
Outcome measures
Primary outcome
Visceral and subcutaneous adipose tissue susceptibility and permissiveness to SARS-CoV-2 infection.
Secondary outcome
The response of adipose tissue-derived factors on epithelial/endothelial cell behaviour?
Background summary
Most of the SARS-CoV-2 infected patients admitted to the ICU with respiratory failure had central obesity, extensive visceral fat and a Body Mass Index (BMI) of 25 kg/m2 or higher (mean 30 kg/m2). Recent findings from the UK, in the largest cohort study to date, confirm that the likelihood of hospital death due to SARS-CoV-2 is associated with obesity severity. Circulating adipose tissue (AT)-derived mediators such as leptin are known to be associated with BMI and are known to have immunomodulating properties which may prime obese individuals to infection resulting in an exaggerated response. We therefore postulate that excess adipose tissue, its distribution and secreted mediators play an important role in the type of immune response and subsequently in the progression towards respiratory insufficiency in patients with SARS-CoV-2.
Study objective
We hypothesize that excess adipose tissue, its distribution and secreted mediators play an important role in the type of immune response and subsequently in the progression towards respiratory insufficiency in COVID-19 patients.
Study design
2 adipose tissue samples during surgery of the patient (bariatric surgery) and 1 adipose tissue sample from lean individuals undergoing abdominal surgery
Intervention
We will collect human visceral and subcutaneous adipose tissue samples in order to investigate the adipose tissue responses to ex vivo SARS-CoV-2 infection. Small adipose tissue samples (subcutaneous and visceral) will be collected from patients undergoing either bariatric surgery (obese) or elective abdominal surgery (visceral only) (lean).
Inclusion criteria
Obese: Healthy participants, male and female aged between 18-65years old with a BMI>40.
Lean: Healthy participants, male and female aged between 18-65years old with a BMI<25.
Exclusion criteria
Diabetes mellitus, hypertension, metabolic syndrome, asthma, immune disease such as Crohn colitis, rheumatic disease, cancer, use of soft/hard drugs or smoking. Previous COVID-19 infection.
Design
Recruitment
IPD sharing statement
Plan description
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL9141 |
| Other | METC UMCG : 202000929 |